Clinical Trials Actively Recruiting

Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below.

Request an Appointment Refer a Patient NCI Dictionary of Cancer Terms Clinical Trials App

Hide Search Criteria

Cancer Category

Enter Keyword

Clinical Trial Phase

Therapies Involved

Device Involved

Study Site

NCT ID

KCI Trial ID

Drug Involved

Principal Investigator

Clear Search

Results 1 - 10 of 10

A first-in-human, open-label Phase 1/2 study to evaluate the safety and anti-tumor activity of ANV600 as single agent and in combination with pembrolizumab in participants with relapsed/refractory advanced solid tumors.
Objective:

Phase I (dose escalation)

Primary Objectives:

To identify the MTD and/or RP2D of ANV600 single agent and in combination with pembrolizumab

Secondary Objectives:

To characterize the PK of ANV600 single agent and in combination with pembrolizumab after single dose and repeated dosing

To evaluate the prevalence and incidence of immunogenicity of ANV600

To describe the anti-tumor activity of ANV600 as single agent and in combination with pembrolizumab

Phase II

Primary Objectives:

To assess the anti-tumor activity of ANV600 as single agent and in combination with pembrolizumab

Secondary Objectives:

To assess the anti-tumor activity of ANV600 as single agent and in combination with pembrolizumab

To assess the safety and tolerability ANV600 single agent and in combination with pembrolizumab for each cohort and in the overall study population

To characterize the PK of ANV600 single agent and in combination with pembrolizumab after single dose and repeated dosing

To evaluate the prevalence and incidence of immunogenicity of ANV600
Cancer Categories:
Lung,Skin
Principal Investigator:
Shao, Yusra
Karmanos Trial ID:
2024-070
Age Group:
Adult
Phase:
Phase I/II
Learn More
A Phase 1a/1b open-label, multicenter, dose-escalation, and dose expansion study to evaluate the safety and activity of TEV-56278, as a single agent and in combination with pembrolizumab, in participants with selected locally advanced or metastatic solid tumors
Objective:

Part 1

Primary Objectives:

To characterize the safety and tolerability of TEV-56278 in the trial population

To determine a RP2D

Secondary Objectives:

To characterize the serum pharmacokinetics of TEV-56278 in the trial population

To evaluate the antitumor activity of TEV-56278 in the trial population

Part 2

Primary Objectives:

To evaluate antitumor activity of TEV-56278 in the trial population

Secondary Objectives:

To characterize the serum pharmacokinetics of TEV-56278 in the trial population

To determine the safety and tolerability of TEV-56278 in the trial population

To evaluate other measures of antitumor activity of TEV-56278 in the trial population
Cancer Categories:
Brain and Nervous System,Breast,Gastrointestinal (GI),Genitourinary (GU),Gynecologic,Head and Neck,Lung,Skin
Principal Investigator:
Saif, Wasif
Karmanos Trial ID:
2024-045
Age Group:
Adult
Phase:
Phase I
Learn More
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BGC515 Capsules in Patients with Advanced Solid Tumors
Objective:

Part I: Dose Escalation Phase

Primary Objectives:

To evaluate the safety and tolerability of BGC515 Capsules in patients with malignant mesothelioma (MM), epithelioid hemangioendothelioma (EHE), or other advanced solid tumors.

To explore the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD).

Secondary Objectives:

To evaluate the pharmacokinetics (PK) of BGC515 Capsules in patients with MM, EHE, or other advanced solid tumors.

To preliminarily evaluate the efficacy of BGC515 Capsules in patients with MM, EHE, or other advanced solid tumors.

Part II: Dose Expansion Phase

Primary Objectives:

To further evaluate the safety and tolerability of BGC515 Capsules in patients with MM, EHE, glioblastoma, or other advanced solid tumors including those with NF1/2 deficiency, YAP/TAZ fusion, LATS1/2 mutation, MST1/2 mutation, so as to determine the recommended phase 2 dose (RP2D).

To evaluate the preliminary efficacy of BGC515 Capsules in patients with MM, EHE, glioblastoma, or other advanced solid tumors including those with NF1/2 deficiency, YAP/TAZ fusion, LATS1/2 mutation, MST1/2 mutation.

Secondary Objectives:

To evaluate the PK of BGC515 Capsules in patients with MM, EHE, glioblastoma, or other advanced solid tumors including those with NF1/2 deficiency, YAP/TAZ fusion, LATS1/2 mutation, MST1/2 mutation.
Cancer Categories:
Breast,Gastrointestinal (GI),Genitourinary (GU),Head and Neck,Lung,Skin
Principal Investigator:
Winer, Ira
Karmanos Trial ID:
2024-064
Age Group:
Adult
Phase:
Phase I
Learn More
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of GSK5764227 in Participants with Advanced Solid Tumors
Objective:

Phase 1a dose escalation

Primary Objectives:

To determine the MTD/MAD and evaluate the safety and tolerability of GSK5764227 in participants with advanced solid tumors.

Secondary Objectives:

To evaluate the PK profile of GSK5764227 in participants with advanced solid tumors.

To evaluate the clinical activity of GSK5764227 in participants with advanced solid tumors

To evaluate the immunogenicity of GSK5764227 in participants with advanced solid tumors.To evaluate the immunogenicity of GSK5764227 in participants with advanced solid tumors.

Phase 1b dose expansion

Primary Objectives:

To evaluate the clinical activity of GSK5764227 in participants with ES-SCLC or advanced solid tumors.

Secondary Objectives:

To evaluate the safety and tolerability of GSK5764227 in participants with ES-SCLC or advanced solid tumors

To evaluate additional measures of clinical benefit of GSK5764227 in participants with ES-SCLC or advanced solid tumors.

To evaluate the PK profile of GSK5764227 in participants with ES-SCLC or advanced solid tumors.

To evaluate the immunogenicity of GSK5764227 in participants with ES-SCLC or advanced solid tumors.
Cancer Categories:
Breast,Gastrointestinal (GI),Genitourinary (GU),Gynecologic,Lung,Skin
Principal Investigator:
Saif, Wasif
Karmanos Trial ID:
2024-073
Age Group:
Adult
Phase:
Phase I
Learn More
A phase I dose-escalation and metabolomics study of metformin combined with chemotherapy and/or immunotherapy in solid malignancies
Objective:

Primary Objectives:

Evaluate the dose limiting toxicities (DLTs) of metformin alone and in combination with chemotherapy and/or immunotherapy (IO) in patients with solid malignancies

Determine the maximum tolerated dose (MTD) of metformin in combination with chemotherapy and/or IO in patients with solid malignancies

Secondary Objective:

Assess efficacy parameters
Cancer Categories:
Breast,Gastrointestinal (GI),Gynecologic,Lung,Skin
Principal Investigator:
Saif, Wasif
Karmanos Trial ID:
2024-050
Age Group:
Adult
Phase:
Phase I
Learn More
An Open-Label, Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of the CTPS1 Inhibitor STP938 in Adult Subjects with Advanced Solid Tumors, With a Safety Expansion in Advanced CTPS2 Null Ovarian Cancer
Objective:

Primary Objectives:

Evaluate the safety and tolerability of single agent STP938

To determine the RP2D for STP938.

Secondary Objectives:

Evaluate the PK of STP938

Evaluate the preliminary clinical activity of single agent STP938.
Cancer Categories:
Brain and Nervous System,Gastrointestinal (GI),Genitourinary (GU),Gynecologic,Head and Neck,Lung,Skin
Principal Investigator:
Winer, Ira
Karmanos Trial ID:
2024-072
Age Group:
Adult
Phase:
Phase I
Learn More
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL - 2 Superkine, Administered Alone or in Combination with Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors
Objective:

Dose Escalation (Monotherapy)

Primary Objectives:

To evaluate safety and tolerability of MDNA11 administered in patients with advanced solid tumors

To identify RDE and/or MTD of MDNA11.

Secondary Objectives:

To assess anti-tumor activity of MDNA11

To assess pharmacokinetic (PK) profile of MDNA11

To assess immunogenicity of MDNA11

To assess pharmacodynamic effects of MDNA11

Dose Expansion (Monotherapy and Combination Therapy)

Primary Objectives:

To further evaluate safety and tolerability of MDNA11 (alone or in combination with pembrolizumab)

To assess anti-tumor activity of MDNA11 (alone or in combination with pembrolizumab)

Secondary Objectives:

To assess pharmacodynamic effects of MDNA11 (alone or in combination pembrolizumab) in peripheral blood

To assess pharmacodynamic effects and immune response of MDNA11 (alone or in combination pembrolizumab) in tumor tissue

To further assess PK profile of MDNA11

To assess immunogenicity of MDNA11 (alone or in combination pembrolizumab)
Cancer Categories:
Breast,Gastrointestinal (GI),Genitourinary (GU),Gynecologic,Head and Neck,Lung,Skin
Principal Investigator:
Winer, Ira
Karmanos Trial ID:
2023-053
Age Group:
Adult
Phase:
Phase I/II
Learn More
AN OPEN-LABEL PHASE 1/2A STUDY OF GV20-0251 MONOTHERAPY AND GV20-0251 IN COMBINATION WITH PEMBROLIZUMAB IN PARTICIPANTS WITH ADVANCED AND/OR REFRACTORY SOLID TUMOR MALIGNANCIES
Objective:

Part A

Primary Objectives:

To characterize the safety and tolerability of GV20-0251 and establish the MTD and/or the RP2D of GV20-0251

Secondary Objectives:

To characterize the PK of GV20-0251

To characterize the immunogenicity of antiGV20-0251 ADA and nADA

To evaluate the preliminary anti-tumor activity of GV20-0251

Part B

Primary Objectives:

To evaluate the ORR per RECIST version 1.1 of GV20-0251 in different tumor types

Secondary Objectives:

To characterize the safety of GV20-0251

To characterize the PK of GV20-0251

To characterize the immunogenicity of GV20-0251

To evaluate the anti-tumor activity of GV20-0251
Cancer Categories:
Gastrointestinal (GI),Genitourinary (GU),Head and Neck,Lung,Skin
Principal Investigator:
Shao, Yusra
Karmanos Trial ID:
2023-106
Age Group:
Adult
Phase:
Phase I
Learn More
Open Label, Multicenter, Phase 1 Study to Evaluate the Maximum Tolerated Dose of Orally Administered CB-03-10 with Dose Expansion Phase, in Subjects with Advanced Solid Tumors
Objective:

Primary Objectives:

Determine the maximum tolerated dose (MTD) of CB-03-10 in subjects with advanced solid tumors

Determine the dose-limiting toxicity (DLT) of CB-03-10 in subjects with advanced solid tumors

Secondary Objectives:

Determine a recommended Phase 2 dose (RP2D) of CB-03-10

Determine the safety profile of CB-03-10 in subjects with advanced solid tumors

Evaluate the activity (response rate, PFS, and OS) of CB-03-10 in subjects with specific solid tumors (e.g., relapsed/refractory pancreatic adenocarcinoma, androgen independent prostate adenocarcinoma, relapsed/refractory triple-negative breast adenocarcinoma)

Characterize the pharmacokinetics (PK) of CB-03-10 and its metabolite CB-03-05 as well as cortexolone in plasma and urine.
Cancer Categories:
Brain and Nervous System,Breast,Gastrointestinal (GI),Genitourinary (GU),Gynecologic,Head and Neck,Lung,Other,Sarcoma,Skin
Principal Investigator:
Winer, Ira
Karmanos Trial ID:
2022-036
Age Group:
Adult
Phase:
Phase I
Learn More
Use of [F-18] FLT for Imaging with Positron Emission Tomography (PET)
Objective:

This pilot study will evaluate the use of [F-18] FLT and PET to measure tumor proliferation and the activity of thymidine kinase. This study may also assess the changes that occur after therapy. Finally we may compare the retention of [F-18] FLT in comparison to that of routine clinical measurements, such as CT, MRI or other imaging studies. One goal of this study is to better understand the abnormalities of thymidine metabolism in tumors in vivo. We may also compare imaging proliferation data using [F- 18] FLT to measurements of gene expression of proliferative and biochemical pathways made on tumor specimens obtained at biopsy.
Cancer Categories:
Brain and Nervous System,Breast,Gastrointestinal (GI),Genitourinary (GU),Gynecologic,Head and Neck,Hematologic (Blood Cancers),Lung,Other,Sarcoma,Skin
Principal Investigator:
Shields, Anthony
Karmanos Trial ID:
2006-127
Age Group:
Adult
Phase:
N/A
Learn More